Ceribell, Inc. (CBLL) - Form 8-K Summary
Business Context and Reporting Period
Ceribell, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 24, 2026. The filing serves to announce the company's financial results for the fiscal quarter ended December 31, 2025. The company is an emerging growth company and its common stock trades on The Nasdaq Stock Market LLC under the symbol CBLL.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K filing acts as a notification that a press release containing these details has been issued. The actual financial data is contained in Exhibit 99.1 (Press Release), which is incorporated by reference but not detailed within the body of this specific 8-K document.
Material Changes
The filing text does not provide specific data to compare current period results against the prior comparable period. Investors must refer to the referenced press release (Exhibit 99.1) for year-over-year or quarter-over-quarter performance analysis.
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference in other filings except as expressly set forth.
Key Facts for Investor Verification
- Verify the specific revenue and net loss figures in the press release (Exhibit 99.1) dated February 24, 2026.
- Confirm the company's cash position and burn rate as of December 31, 2025, to assess liquidity runway.
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are critical for this biotechnology firm.
- Note that the 8-K itself does not contain the financial data; the press release is the primary source for the quarter's results.